

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

For the Japanese version, please refer to the Japanese PR of "Notice of Publication of Transcript of logmi Finance Financial Results Briefing for the Fiscal Year Ending June 2026" published on August 21, 2026.

Financial Results Report

FY06/2026

OLBA HEALTHCARE HOLDINGS, INC.
(formerly KAWANISHI HOLDINGS INC.)

This presentation includes machine translation.
Please consider that some content may not be perfectly accurate or contextually appropriate.
(Securities code: 2689)



[Title]

OLBA HEALTHCARE HD reports record-high sales and gross profit; sales of its "Temasac" automated payment machine for clinics continue to be strong.

[Lead]

The following is a transcription of the financial results presentation of OLBA HEALTHCARE HOLDINGS, Inc. for the first half of the fiscal year ending June 30, 2026, which was announced on August 21, 2026.

[Speaker]

Yohei Maeshima, President and CEO, OLBA HEALTHCARE HOLDINGS, Inc.

Contents

Contents

- ◆ **Summary of FY06/2026 Results**
- ◆ **Shareholder Returns, Profitability Analysis, etc.**
- ◆ **Progress of the Medium-Term Management Plan**
- ◆ **Management integration and name change**
- ◆ **Reference Materials**

This is Maeshima, president of Orba Healthcare Holdings. Thank you very much. While you are busy today, we thank you for viewing our group's results briefing. Today, we will proceed with the content as shown on the slide.


Domestic Market Size of Medical Devices

Domestic market size of medical devices

Stable market growth despite policies to curb medical costs

- Recovering from the Impact of the New Corona and Stable Market Expansion
- Market expansion due to increase in number of surgeries and introduction of new products

Forecast for FY2025 is ¥3.895 trillion



This section presents an overview of the results for the fiscal year ended June 2026. The size of the domestic market for medical devices has grown steadily at a rate of 2% to 3% per year, despite government measures to contain healthcare costs.

It is expanding and is expected to be 3.895 trillion yen in fiscal 2025.

According to 2023 statistics, the amount of excess imports of medical devices has reached approximately 2 trillion yen per year, indicating the high share of overseas medical devices in the domestic market.

Recent Market Conditions and Our Response Policies

Recent Market Environment and Our Response Policies

■ Global inflation and depreciation of the yen

- Prices of medical devices, many of which are overseas products, continue to trend upward
- ⇒ Implemented measures to expand sales activities and improve purchasing



■ Labor shortages, delays in digitalization, and restrained capital investment at medical institutions

- Deterioration in the business environment at some medical institutions due to a decrease in subsidies, increase labor costs and resource prices, etc.

⇒ Streamlining medical operations through new businesses and expanding sales to non-medical institutions

⇒ Medical fee plus revision (+2.22% overall)



■ Changes in the healthcare system toward 2040

- Consolidation of advanced and specialized medical in certain large hospitals
- Functional differentiation of hospitals (acute phase, elderly emergency, home medical care and nursing care collaboration)

progresses

⇒ Strengthen cooperation with medical device manufacturers and provide support to core hospitals for major customers

⇒ Able to handle all rounds in the Orba Group, from acute care to home care

5
©ORBA HEALTHCARE HOLDINGS, Inc.
※ From the Ministry of Health, Labour and Welfare's Guidelines for the Formulation of Regional Medical Care Concepts on July 3, 2026

This report describes the environment surrounding us and our responses to these issues. First, the global inflation and the depreciation of the yen have led to a continuing upward trend in the prices of medical devices, which have a large number of overseas products. We are implementing measures such as expanding sales activities and improving purchasing.

Second, in addition to personnel shortages and delays in digitalization, there are signs that medical institutions will refrain from making capital investments. The decline in subsidies for responding to the new coronavirus and increases in labor costs and resource prices caused a deterioration in the business environment at some medical institutions.

Against this backdrop, we are making proposals to improve the efficiency of health care operations through new businesses, and are also engaged in the sales business to non-medical institutions.

In fiscal 2026, the medical fee revision was a positive revision of 2.22% from the previous negative revision of 0.12%. This is expected to improve the management of medical institutions and improve our business environment.

Third, we will respond to changes in the healthcare system toward 2040. On July 3, 2026, the Ministry of Health, Labour and Welfare published the Guidelines for the Formulation of Regional Medical Care Concepts. The government aims to consolidate highly specialized medical care to specific large-scale hospitals and maintain a high-quality medical care delivery system. Going forward, hospitals are expected to

become increasingly functionally differentiated, such as the acute phase, the elderly acute care, and home medical care and nursing care collaborations.

For core hospitals in the region that are our main customers, we will strengthen cooperation with medical device manufacturers and continue to provide support. At the same time, we will respond to an all-round from the acute stage to home nursing care by leveraging our strengths as a general medical trading company.

Performance Topics: Our Status

Performance Topics: Our Status

■Sluggish growth in operating income in the mainstay medical equipment business

- Sales grew steadily, but profit margins declined due to tough price negotiations.
 - ⇒ Strong performance in the orthopedics field due to customer acquisition in the Kansai area
 - ⇒ Due to deterioration in the management of medical institutions, the replacement of equipment and fixtures was postponed.
- Sales of automatic checkout machines in new businesses remained strong.
- SG&A costs increased due to one-time costs related to system security and management integration



■Steady growth in SPD and nursing care products businesses

- SPD Business: Increased number of SPD agreements
 - ⇒ Strong sales of inventory management systems for small and medium medical institutions
- Nursing care products: Mainstay rental business increased 6.9% year on year
 - ⇒ Steady growth due to contribution from the Shikoku area developed in the previous fiscal year



6

COLBA HEALTHCARE HOLDINGS, Inc.

I would like to talk about the performance topics of our group. The first of the main points is that operating income in the mainstay medical device business has been sluggish. Although sales grew steadily, margins declined due to tough price negotiations on the part of medical institutions.

Specifically, while the orthopedics field was favorable due to the acquisition of customers in the Kansai area, there were cases in which the renewal of equipment and fixtures was postponed due to the deterioration in the management of medical institutions.

Sales of the new vending machine business continue to be strong. In addition, system investment and security-related expenses, as well as one-time costs related to business integration, have pushed up SG&A expenses, causing operating income to stagnate.

Second, SPD Business and the Nursing Care Products Business showed steady growth. In SPD business, the number of contracts increased and sales of inventory control systems for small and medium-sized medical institutions were strong.

In the nursing care products business, the rental business, our mainstay business, performed solidly, increasing 6.9% year on year. This is attributable to the expansion of transactions in the Shikoku area, which was cultivated in the previous fiscal year.

Consolidated results for the fiscal year ended June 2026

Consolidated Financial Results for the Fiscal Year Ended June 2026

Net sales and gross profit reached record highs, but profits declined

	Millions of yen	Comparison with budget	YoY change
Net sales	126,595	Δ1.1%	+3.2%
Gross profit	14,178	Δ4.6%	+1.9%
Gross profit margin	11.20%	Δ0.41	Δ0.14
SG&A expenses	12,498	Δ2.8%	+4.8%
Operating income	1,679	Δ16.0%	Δ15.2%
Recurring Profit	1,664	Δ13.7%	Δ15.2%
Net income attributable to owners of parent	1,112	Δ15.8%	Δ22.2%

Net income per share ¥187.67

7


COOLBA HEALTHCARE HOLDINGS, Inc.

Consolidated financial results for the fiscal year ended June 2026. Net sales were 126.595 billion yen, operating income was 1.679 billion yen, ordinary income was 1.664 billion yen, and profit attributable to owners of parent was 1.112 billion yen.

Net sales and gross profit reached record highs, but sale income and other items fell short of the budget and the previous fiscal year due to an increase in SG&A expenses.

Net income per share was ¥187,67.


[Consolidated Net Sales] Historical Trends



Consolidated net sales for the past five years are shown below. Despite the impact of the new coronavirus infectious disease, inflation, and the depreciation of the yen, our business results continue to steadily increase every fiscal year. In the fiscal year ended June 2026, we recorded record highs, resulting in an increase in revenues for the sixth consecutive year.

[Consolidated Operating Income] Historical Trends


[Consolidated operating income] Historical trends



The table below shows the trends in consolidated operating income for the past five years. In recent years, profits have been sluggish, and in the year ended June 31, 2026, profits declined for two consecutive years.

Fiscal 2026 Performance by Segment

Business Segment Results for the Fiscal Year Ended June 2026



[FY06/2026] Net sales (operating profit)

※Sales include inter-segment sales

119.4 billion yen
(1.46 billion yen)



Medical equipment business
Total partners in the medical field

6 billion yen
(110 million yen)



SPD business
Medical equipment management service
in the hospital

2.9 billion yen
(240 million yen)



Nursing Care Products Business
Rental and sales of home nursing care
products

10


COLBA HEALTHCARE HOLDINGS, Inc.

Net sales and operating income by business segment are shown below. The mainstay Medical Equipment segment accounts for 93.0% of net sales, followed by SPD segment (4.7%) and the Nursing Care Products segment (2.3%).

In the medical equipment business, we are developing our business as a total partner in the medical field. SPD business provides services that comprehensively support the management of medical equipment within hospitals. In the nursing care products business, we rent and sell home nursing care products to support nursing care at home.

Operating income FY06/2026

Factors behind Changes in Operating Income for the Fiscal Year Ended June 2026



This section explains the factors behind the increase and decrease in operating income for the fiscal year ended June 2026 compared to the fiscal year ended June 2025. Consumables in the medical equipment business increased steadily, but a decrease in sales of facilities and equipment and an increase in SG&A expenses associated with investments in human resources and IT systems were substantially negative.

Furthermore, one-time costs related to the business integration were incurred in corporate SG&A expenses, resulting in a ¥300 million year-on-year decrease in operating income to ¥1.679 billion.

Medical Equipment Business

Medical equipment business




Total partners in the medical field

Millions of yen	Actual	Comparison with budget	YoY change
Net sales ^{※1}	119,453	Δ0.8%	+3.1%
Operating income	1,466	Δ16.2%	Δ17.3%



Medical equipment [93.0%]



Millions of yen	Sales Results ^{※2}	YoY change
Kawanishi Corporation	79,461	+3.0%
Sansei Medical	27,281	Δ0.8%
Nikko Medical Instruments	13,119	+7.1%

※1 Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales

※2 Sales results of individual companies include the amount of transactions between group companies

12

©OLBA HEALTHCARE HOLDINGS, Inc.

This is the results of our medical equipment business. Net sales increased 3.1% to ¥119.453 billion and operating income decreased 17.3% to ¥1.466 billion.

Please refer to the lower right of the slide for the year-on-year change in net sales by operating company. Despite an increase in net sales, operating income decreased due to the difficulty of passing on the increase in purchase prices to prices and an increase in selling, general and administrative expenses.

Medical Equipment Business Consumables

Medical Equipment Business Consumables

Net sales ¥107 billion up 3.5% year on year

Millions of yen

Product Classification	Net sales	YoY change	Points of sub-segments
Surgical consumables	51,536	+2.1%	Steady sales of diabetes-related products, a key strategy, and an increase in the number of surgical procedures Internal medicine (including diabetes) +6.1%, digestive endoscopes +5.7% Surgery +3.6%, Ophthalmic Δ 3.8%
Orthopedic consumables	30,276	+4.8%	Strong sales of consumables related to sales of robotics and navigation systems Spine +7.3%, artificial joint +4.6%
Cardiovascular consumables	25,212	+4.7%	Strong sales of new products related to arrhythmia treatment Catheter ABL*+7.2%, arrhythmia-related implants +3.7% Cardiac and Vascular Surgery +3.6%

* ABL: Therapy in which a portion of the heart is catheterized for a tachyarrhythmia, such as auricular fibrillation, to be ablated or frozen

※ Net sales (including changes from the previous fiscal year) are calculated based on management accounting before the adoption of the new revenue recognition standard.



Ultrasound scalpel

Johnson & Johnson K.K.
From our website (<https://www.jji.co.jp/>)



Artificial knee joint

Zimmer Biomet website
From <https://www.zimmerbiomet.com/jp/>



Pacemaker

Medtronic website
From <https://www.medtronic.com/>

13

OOBA HEALTHCARE HOLDINGS, Inc.

Overall sales of consumables in the medical equipment business amounted to ¥107 billion, an increase of 3.5% from the previous fiscal year. We will explain the breakdown in three product categories. First of all, in surgical consumables, overall sales increased 2.1% year on year due to an increase in the number of procedures performed and steady sales of diabetes-related products, a priority measure.

In orthopedic consumables, sales of consumables related to robotic surgery and navigation systems were strong, resulting in an overall increase of 4.8% over the previous fiscal year.

In cardiovascular consumables, sales of new products related to arrhythmia treatment contributed to overall sales growth of 4.7%. New products include Pulse Field Ablation, a type of catheter ablation used in the treatment of atrial fibrillation.

This method does not use heat, but destroys only the cardiovascular cells that cause arrhythmia by high-voltage electric pulses. Compared to conventional methods, this method is characterized by its ability to reduce the risk and physical burden of patients. These characteristics have led to widespread adoption in the treatment field in recent years. As described above, net sales for all product categories were positive compared with the previous fiscal year.

Medical Equipment Business Facilities and Equipment

Medical Equipment Business Equipment

Sales ¥14.2 billion down 3.0% year on year

Points of Equipment Sales

◆Decline in willingness to invest in facilities due to deterioration in the business environment of hospitals

◆Sales of automated payment machines for clinics were steady.



Pulmotor

Philips website
Then (<https://www.philips.co.jp/healthcare/>)



With analysis function
Vital signs monitor

Fukuda Electronic Website
From (<https://www.fukuda.co.jp/>)

Regarding equipment in the medical equipment business. Net sales were ¥14.2 billion, down 3.0% from the previous fiscal year. Sales were sluggish, as rising personnel costs and other expenses led to a deterioration in the operating environment for hospitals, which led to a trend to refrain from capital investment.

Meanwhile, sales of automated payment machines for clinics remained steady.

Medical products distribution specialist

Millions of yen	Actual	Comparison with budget	YoY change
Net sales [※]	6,096	Δ1.2%	+6.6%
Operating income	119	Δ8.4%	+5.0%
Total number of subscribers	※Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales		
79 direct			
FC 2			

- ◆ Review of commodity management service fees
- ◆ Steady sales of Medilia® inventory control system
- ◆ Passing on increases in purchase prices to higher prices and making improvements in purchases



Goods management



Information management



Purchasing management



15

© OOLBA HEALTHCARE HOLDINGS, Inc.

This is the performance of SPD business. Net sales were ¥6.096 billion, an increase of 6.6% year on year. This was mainly due to a review of the fee for the goods management service at existing contract medical facilities and steady growth in sales of Medilia, an inventory management system for small and medium-sized medical institutions.

Operating income rose 5.0% year on year, reaching ¥119 million, as a result of efforts to pass on the increase in purchase prices to prices and to improve purchases.

Current status of SPD business and future initiatives

Current Status of SPD Business and Future Initiatives

HOSNET HOSNET-JAPAN INC.

● Acquisition of new customers and improvement of revenue

- April 2026 Kagawa Center was opened. Plans to expand existing centers
- Develop customers in the Chugoku-Shikoku area
- Proposals for hospital management support, such as purchasing price reductions and insurance



● Wide-area sales of Medilia ® inventory control system

- Voluntary investment type at small and medium hospitals
- Simple and accurate inventory management
- Inexpensive billing and remote maintenance



YouTube video <https://www.youtube.com/watch?v=iYxAGT6Ud>

● Problem solving by the new company "MJC Corporation"

- Established a joint venture with media HD in the same industry
- Started solving industry issues in master maintenance in July 2026
- Building Systems to Support Industry Standards and Japan's Medical Care in the Event of Disasters

16
COLBA HEALTHCARE HOLDINGS, Inc.

This section describes the current status of SPD business and future initiatives. In SPD business, Kagawa Center was newly established in April 2026. We plan to continue to relocate and expand our existing centers. We will promote proposals for hospital management support, such as customer development in the Chugoku-Shikoku area, purchasing price reductions, and insurance claim omission confirmation.

We will also continue to focus on the wide-area sales of Medilia, a proprietary inventory control system for small and medium-sized hospitals that we have developed in-house that enables simple and accurate inventory control. Because Medilia can be operated by hospital staff, it can be sold in a wide range of areas. There is also a video introducing YouTube, so please take a look.

This section introduces the initiatives of the new company, MJC Co., Ltd. MJC, which was established jointly with the media holding company in the same industry, began solving industry issues in the maintenance of medical equipment masters in July 2026.

Currently, as medical device materials become more sophisticated, product information is becoming enormous, while the management systems of wholesalers and medical institutions are becoming more personalized. Accordingly, cost increases and registration delays due to manual input and other factors are becoming industry-wide issues. MJC aims to create a system for quickly and efficiently registering the product information of medical device manufacturers with the respective systems. In this way, MJC will contribute to the promotion of medical DX.

Nursing Care Products Business

Nursing Care Products Business

Total support for nursing care products

Millions of yen	Actual	Comparison with budget	YoY change
Net sales ※	2,910	Δ1.3%	+4.8%
Operating income	245	Δ0.6%	+19.6%

※ Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales

- ◆ Continued demand for home medical care and in-home nursing care
- ◆ Contribution from sales in the Shikoku area developed in the previous fiscal year
- ◆ Mainstay nursing care product rentals up 6.9% YoY
- ◆ Significant increase in profit due to the absence of one-time costs for opening sales offices in the previous fiscal year



Rental



Sales



Renovation




17

©OLBA HEALTHCARE HOLDINGS, Inc.

Results in the nursing care products business. Sales of the mainstay nursing care product rental increased 6.9% year on year, supported by continued high demand for home medical care and in-home nursing care, and contributions from growth in the Shikoku area, which was newly developed in the previous fiscal year.

Segment sales increased 4.8% to ¥2.91 billion and operating income increased 19.6% to ¥245 million.

Current Status and Future Initiatives in the Nursing Care Products Business



- **In-house construction of residential remodeling for nursing care**

- Strengthen customer service by enhancing follow-up system
- Promote sales activities using ICT

- **Cultivating new users**
- **Providing Safety and Security Services**

- Strengthen transactions with nursing care facilities
- Hearing aids sales and wheelchair repair services



18


CARE HOLDINGS, Inc.

In addition, we will strengthen product sales and service provision for nursing care facilities, and promote sales of hearing aids and wheelchair repair services. We will also continue to conduct cross-selling, such as sales of goods to rental customers and proposals for home renovation.

Regarding the development of bases, following the opening of sales offices in Onomichi City, Hiroshima Prefecture in 2022 and in Kochi Prefecture in 2025, we will continue to open additional new stores in the Setouchi area. We anticipate continued growth in the home nursing care equipment business in the future, in part due to government policies to encourage the transition from hospitals to home care.

Dividends and Future Dividend Policy

Dividend status and future dividend policy



The following is an explanation of shareholder returns and profitability analysis. First, we will discuss our dividend status for the past 10 years and our dividend policy going forward. We plan to pay a dividend of ¥80 per share for the fiscal year ending June 2024 and a dividend of ¥80 per share for the fiscal year ending June 2026.

The blue line chart shows the evolution of DOE, or dividends on equity. DOE at the end of June 2026 was 3.9%, which is relatively high, with the average of 2% of the total number of listed companies. The dividend yield shown in the orange line graph is also relatively high at 4.2% at the end of June 2026.

The Company will announce its dividend policy after the management integration as soon as it is finalized.

Current Shareholder Benefit QUO Card

Current QUO shareholder benefit cards

Number of years held	Ownership Number of Shares Held	QUO card
Over 1 year Less than two years	100 to less than 1000 shares	1000 yen
	1000 shares or more	4000 yen
3 years or more	100 to less than 1000 shares	2000 yen
	1000 shares or more	5000 yen



21


©OLBA HEALTHCARE HOLDINGS, Inc.

This section introduces the current shareholder benefit program. Benefits are listed in the table. Shareholders who have held our shares for more than one year have a "QUO card" with the face value shown in the table, depending on the number of years and the number of shares held.

The policy of the shareholder benefit program after the management integration will also be announced as soon as it is finalized.

Cost of Capital and Profitability of Capital Analysis

Analysis of Capital Cost and Capital Profitability




This is the current state of the Group's cost of capital and profitability of capital. We estimate our cost of equity to be around 6 percent. Equity spreads, calculated by subtracting the cost of equity from ROE, have ranged between 2% and 7%.

Although we are maintaining profitability in excess of our cost of equity, as shown on the slide, our ROE declined this year.

Going forward, we will continue to invest for growth and development and strive to improve profitability based on the medium-term plan and the management integration plan.

Initiatives to Improve PBR

Initiatives to Improve PBR



※ Figures in parentheses are as of June 30, 2026 for PBR and the results for the previous fiscal year for others. Figures for the TSE are as of June 2026.

©OLBA HEALTHCARE HOLDINGS, Inc.


This is an initiative to improve our PBR. Our PBR as of the end of June 2026 was 0.86 times. The weighted average PBR of wholesalers in the TSE Standard Market is 0.8 times, exceeding the market average but falling below 1.0 times. We aim to more than double our PBR to 1.0 in the future and will strive to make further improvements.

PBR is broken down into ROE and PER, but we recognize the importance of improving the net income margin and expected growth rate in particular in order to improve PBR. In terms of net income as a percentage of net sales, we will raise productivity through more efficient use of DX・AI and promote the development of new high-value-added businesses.

With regard to the expected growth rate, we aim to further improve PBR by improving the ratio of overseas businesses, cultivating new businesses, and raising awareness through aggressive IR activities.

Initiatives for sustainable VISION2030 growth and shareholder returns

VISION2030 Sustainable Growth and Shareholder Returns Initiatives



25

COOLBA HEALTHCARE HOLDINGS, Inc.

I will explain the progress of the medium-term management plan. We have set the “VISION2030” as our vision for the year 2030. We are working to achieve our goals of becoming the best domestic medical device trading company, earning 20% of our operating income from overseas, and bringing more than 30 new products and services to the world.


Going forward, we will continue to support medical institutions and patients to provide a stable supply of medical and nursing care services. At the same time, we will expand new businesses by selling automated payment machines for clinics and low-thermal decomposition upcycle units, and growing our business in Thailand.

Based on the revenues generated by these businesses, we will actively return profits to shareholders while also investing in new businesses in an effort to increase corporate value.

We will also aim for further growth and development of the Group through the management integration with DeVEX Co., Ltd.

Current Medium-Term Management Plan (Formulated in June 2025)

Progress of the Current Medium-Term Management Plan (Formulated in June 2025)



New medium-term management plan after business integration will be announced once finalized

This is the medium-term management plan for the fiscal years ended June 2026 to June 2028. The new medium-term management plan after the management integration will be announced as soon as it is finalized. In the following slides, I will explain the progress of the current plan.

Status of DX Measures

- **Promote further sales support and operational efficiency**
 - Promote the use of generated AI
 - Expanded use of no-code tools
 - CRM, SFA construction: demonstration stage
 - Renovation of groupware: Operations commenced in September 2026
 - Renovation of sales management system: Scheduled to start operation in 2027

DX Human Resource Cultivation Efforts

- Implementation of DX literacy training by e-Learning
- Holding Group study sessions
- Encourage to take IT Passport Examination

[In-house no-code tool utilization study session]



27

©OLBA HEALTHCARE HOLDINGS, Inc.

First, regarding our DX initiatives, we established DX Promotion Office in 2021 to reform the businesses of each Group company. As an ongoing initiative, we are expanding the use of generation AI and no-code tools, which we use in our daily operations. As for no-code tools, we hold study sessions within the company, and we also have the opportunity to introduce our case studies at external events.

We are also in the process of building CRM and SFA, and are currently conducting demonstration tests, and plan to begin using them in stages.

We are currently gradually transitioning to groupware in preparation for full-scale operation in September 2026. We are also in the process of revamping our sales management system. To develop DX human resources, we are expanding our e-learning program, holding group-wide study sessions, and encouraging employees to acquire IT passports.

Logistics innovation

Logistics warehouse construction

• Operation of Li-Flo, an integrated logistics system

Started operation in September 2022 sequentially from the bases of the operating companies' Kawanishi ⇒ Introduction to the entire group is scheduled to be completed



Reinforcement in
inventory control

To reinforce quality
management

Streamlining of
lending business

Effects at Introduction Sites

- Improving the efficiency of product pick and delivery slip output and reducing inventory time through barcode reading and system linkage, etc.


• Shin-Okayama Distribution Center Construction

Decided to construct a new logistics center for the medical equipment business, scheduled to begin operations in July 2027

Purpose of construction

- Streamlining operations, BCP measures, and building new logistics networks
- Hub base for the supply of medical equipment in the Chugoku-Shikoku region

⇒ Based on the philosophy of "do not stop medical care," we will be responsible for the stable supply of medical devices as a base that supports regional medical care.



※ For details, please refer to "Notice Regarding Lease of Fixed Assets by Lease of Consolidated Subsidiaries"

28

COOLBA HEALTHCARE HOLDINGS, Inc.

I will explain about logistics innovation. The integrated logistics system "Li-Flo" has been in operation since 2022, and we plan to complete its introduction to the entire Group in the fiscal year under review.

Li-Flo was developed with the aim of improving quality control, such as strengthening inventory control and expiration date control, and streamlining the lending businesses of orthopedic surgical instruments and other items. Benefits include streamlining product picking operations in warehouses with bar code reading, streamlining delivery note output, and reducing inventory time.

We are also constructing the Shin-Okayama Distribution Center, which is scheduled to begin operations in July 2027. The aim of this center is to streamline operations, address BCP, build a new logistics network, and form hubs for supplying medical equipment in the Chugoku-Shikoku region.

Based on our philosophy of "do not stop medical care," we aim to support regional medical care and provide a stable supply of medical equipment.

Joint Distribution of Medical Equipment in the Kurashiki Area of Okayama Prefecture (from March 2026)

Joint distribution of medical equipment in the Kurashiki area of Okayama Prefecture (from March 2026)

Logistics
• Innovation

Joint distribution of medical equipment at Kurashiki Chuo Hospital

■Background and purpose

- Response to logistics 2024 issues and driver shortages
- Elimination of low loading rate and inefficiency in medical device logistics
- Building a Sustainable Logistics Model Based on the Medium-Term Logistics Plan

⇒ Integrated delivery through joint delivery, route optimization, Initiatives started to improve loading ratio

■Effects and medium-term value of initiatives

- Dramatic improvement in the efficiency of warehousing and inspection operations
- Reduce logistics costs by consolidating vehicles and effectively utilizing space
- Achieving Reduced CO₂ Emissions (ESG and Non-Financial Value)

⇒ Continue efforts to expand into other regions and facilities

Medical equipment trading company in the Okayama area
Joint distribution by two companies



Our subsidiary

Nishinoh Medical Link Co., Ltd. HP (<https://www.jml-west.jp/>)

[Kurashiki Chuo Hospital, Ohara Commemorative Kurashiki Chuo Medical Organization]



Kurashiki Chuo Hospital HP (<https://www.kchmed.or.jp/>)

※For details, please refer to "Notice of Commencement of Demonstration Trial for Joint Distribution of Medical Devices in the Kurashiki Area" and "Notice of Commencement of Full-scale Joint Distribution of Medical Devices in the Kurashiki Area"

COLBA HEALTHCARE HOLDINGS, Inc.

This section explains the joint distribution of medical devices in the Kurashiki area of Okayama Prefecture. In addition to issues such as the 2024 logistics problem and a shortage of drivers, this initiative aims to eliminate low load factor and inefficiencies in medical device logistics.

For Kurashiki Chuo Hospital, we worked with Nishinoh Medical Link Co., Ltd., a company in the same industry, with the aim of optimizing bulk deliveries and delivery routes through joint deliveries and improving load factors.

This initiative has already produced results, and has led to the creation of non-financial value from a ESG perspective as well. This includes significantly streamlining warehousing and inspection operations, controlling logistics costs by consolidating vehicles and effectively utilizing space, and reducing CO₂ emissions by reducing the number of deliveries.

In the future, we will aim to build a sustainable logistics model by improving logistics efficiency for the entire medical device sales trading company by expanding joint delivery regionally.

New businesses ① “Temasac” sales were strong

New Businesses ① Strong sales of Temasac®

株式会社 カワニシバークメド

To foster new businesses
Expansion of the Berkmed business


Establish a solid market foundation with a cumulative total of over 1000 automated payment machines for clinics

① テマサック



2026)

- Introduction results for the fiscal year ended June 2026: 286 units (YoY +31 units)
- Cumulative number of vehicles introduced: 1040 (As of the end of June



Introduction to new businesses. The first is Temasac, an automatic settlement machine for clinics operated by Kawanishi Berkmed Co., Ltd.

Demand for automated payment machines is increasing, particularly in clinics and clinics, which aim to save labor in accounting businesses. Temasac also supports cashless settlement, as it realizes collaboration with the Receipt Computer, a medical fee billing system that is required for medical clerical work.

During the one-year period from July 2025 to June 2026, 286 vehicles were introduced, reaching a cumulative total of 1040 vehicles, exceeding 1000.

“TEMASAC” is sold to clinics in various parts of Japan. About 40% of the customers sold this product occupy the Kanto region. It is sold at seven bases nationwide, and at this time, it has a sales track record in 46 prefectures, excluding Yamagata Prefecture.

OLSTECH®, a low-pyrolysis up-cycle unit



OLSTECH| Three characteristics

- 1) Significant reductions in CO2 and dioxin emissions
- 2) Organic garbage reduced in size to 1/300 volume, secondary use
- 3) Space saving & low running cost (fossil fuel not used)

- Nylon gloves that are disposed of in large quantities in medical and nursing care settings
Developed from disposing of diapers
- Contribute to reducing environmental impact without transporting and incinerating garbage
- There are inquiries from a variety of fields, including apparel and food.

Earnings opportunities outside the medical equipment business

Aiming to expand revenues by accelerating sales and delivery

- Research on environment and safety, osaka university
- Joint development with management centers
- Further product improvements underway

※For more information, please refer to "Notice of Establishment of Subsidiaries" and "Notice of Sales of Natural Decomposition Promotion-Type Up-Cycle Unit OLSTECH Orthtech™"

OLBA HEALTHCARE HOLDINGS, Inc.

31

The following new businesses are introduced. In 2025, companies established Orcido Co., Ltd., a 100% subsidiary. We began sales of OLSTECH, a low-thermal decomposition-type up-cycle unit.

OLSTECH uses chemically reacted heat to significantly reduce CO2 emissions by decomposing waste without burning it. The power supply can be operated from a household power outlet. This product was completed through joint research with the Osaka University Center for Environmental and Safety Research and Management, based on the idea that Nylon gloves and diapers, which are discarded in large quantities on a daily basis in medical and nursing care settings, can be treated with environmental friendliness.

By not transporting or incinerating garbage, we were able to reduce our environmental impact, and we began selling it first for the purpose of decomposing general garbage. Currently, we are receiving inquiries from a variety of fields, including the apparel industry and the food industry.

As a result, it also leads to profit opportunities outside the medical and nursing care fields. Sales results have already increased, and we will continue to accelerate sales and delivery with the aim of expanding revenues.

New Businesses ③ “Babyeets”

New Business③ 「Babyeets®」



To foster new businesses

Newborn Live Distribution & Memorial Movie Creation Service “Babyeets®”



Babyeets® | Three Characteristics

- 01 Easy access to read-only cards
- 02 Real-time video viewing from remote areas
- 03 Provision of memorial video after hospitalization



[Thoughts on development]

- With inspiration and newborn records immediately after delivery
Deliver to families and relatives
- To the promotion of attachment to newborns
Aim to contribute



Left: Memorial movie sample
Right: AI-TV interview video

Launched at Ehime University Hospital in December 2024
Patents have been obtained and are being operated at seven facilities
(as of the end of June 2026).

32

※For more information, see the Newborn Live Distribution & Memorial Movie Creation Service Babyeets Launch Notice.

©2024 KAUANISHI HOLDINGS INC.

In the following new businesses, we will introduce the live distribution of newborn babies for obstetrics and gynecology and Babyeets (Babies) memorial movie creation service.

Babyeets is a service that allows families to view the images of newborns on their smartphones and PCs in real time during the admission of newborns and mothers using a dedicated card. We also provide a memorial video after a hospital is discharged.

This service was developed based on the desire to deliver excitement immediately after birth to families and to promote the formation of attachment to newborns. In December 2024, we began operating the system at Ehime University Hospital, which has also acquired patents. As of the end of June 2026, the system is being operated at seven facilities nationwide.

From QR code in the slide, please also read the sample of the Memorial Movie and the interview video of “Ai TV”.

New Businesses ④ Taiolba Healthcare (from January 2023)

New Businesses ④ Thailand of Healthcare

(from January 2023)

THAI OLBA

To foster new businesses

ASEAN business development

Business Progress



To expand sales of fully automated tablet packaging machines

- Decided to introduce the system to public hospitals following university hospitals and Royal Hospital

[Authorized distributor in the Kingdom of Thailand]

TAKAZONO

Takazono Co., Ltd. :
<https://www.takazono.co.jp/>



Commercialization of Thai-FDA approvals

- Commercialization of regulatory approval teams for application and approval
- Positioning of medical device import manufacturers



Supporting several companies with NDA signing

Activities to expand sales of orthopedic implants

- Launched in December 2025

DiOS Digital Orthopaedic Solutions Co., Ltd.

DIOS: VOOAs



- Apr. 2026 Registration as Thai Innovation List

Promoting sales expansion activities through registration benefits



33

©OLBA HEALTHCARE HOLDINGS, Inc.

I will explain the progress of overseas business in the Kingdom of Thailand. In 2023, we established a joint venture company, Taiolba Healthcare. Following university hospitals and the Royal Hospital, Takazono Co., Ltd. decided to introduce its fully automated tablet dispensing machines to Nakon Nayok Hospital, which is under the jurisdiction of the Thai Ministry of Health.

The hospital is pursuing digitalization and smart hospitalization initiatives with the aim of providing modern medical services and shorten patient waiting times. Among the hospitals in Thailand's Ministry of Health, adoption in hospitals that promote smart hospitals in particular will lead to expectations for future market acquisition.

In addition, the Thai Food and Drug Administration (FDA) is continuing to obtain approval for medical devices and other products with the aim of positioning Taiolba Healthcare as a medical device manufacturer and establishing sales agency rights. As a result of the confidentiality agreement, we refrain from giving specific product names, but support the products of multiple Japanese companies.

Furthermore, we began commercializing these applications and the costs of obtaining approval as revenues. In the sales of orthopedic implants, the products of DiOS Ltd. (Digital Orthopaedic Solutions Co., Ltd.) in Thailand, which we handle, were registered on the Thai innovation listing.

As this registration allows us to enjoy a variety of preferential treatment, we are focusing on and working to expand our market share, particularly in national and public hospitals.

ESG Initiatives

Sustainability

Environment

- Sales of OLSTECH® low-thermal decomposition-type up-cycle unit



↑ low-thermal decomposition-type up-cycle unit "OLSTECH®"

→Carbonate discharged after treatment. Available for building materials and soil improvement materials



Social



[Human Capital Investment/Health Management]

- Increase in male employees taking childcare leave
- Promotion of female employees activities
- External Mentor System
- Target for the ratio of female managers in 2030: 19.0%
- Enhance employee engagement
- Formulation of Health Management Strategy Map
- Long-term revenue support (GLTD) [Contribution to local communities]
- Safe and high-quality medical care
- Provision of nursing care equipment and services

Governance

- Ensure management transparency, efficiency, and soundness. Enhancement of Group Value
- Promote fair competition and business transactions at all times in our employee charter, and strive to raise the ethical awareness of each and every employee.



↑ Corporate Governance Structure

34

COLBA HEALTHCARE HOLDINGS, Inc.

This section introduces our initiatives for sustainability. As part of our ESG initiatives, we hope to contribute to improving the global environment through sales of OLSTECH in the environmental field (E).

In the Social Sector, S, we are committed to human capital investment, health management, and contributions to local communities. With regard to health and productivity management, I use my own background as a medical doctor to actively promote it. In 2026, we were also certified as an excellent health management corporation.

In addition, we are encouraging men to take childcare leave and women to play an active role. In addition to introducing an external mentor system for women, we have set a target of increasing the ratio of women in managerial positions to 19.0% by 2030.

In addition, we introduced a long-term income support (GLTD) system to compensate employees for a portion of their income in the event that they become unable to work for a long period due to illness or injury.

In the area of governance, we strive to raise the ethical awareness of each and every employee by ensuring management transparency, efficiency, and soundness, and by stating in our Employee Charter that "we will endeavor to engage in fair competition and business transactions at any time."

Growth-Oriented Human Resource Development

Human Resources Development as a Source of Growth


■ Systematic human resource development and acquisition of expertise

OLBA Academy, a 30-year-old internal training system

Building expertise and management capabilities

Gradual expansion of e-Learning courses

We provide opportunities for employees to learn according to their stage of development. Enhance employee engagement



[Training for new employees]



OLBA HEALTHCARE HOLDINGS, Inc.

This section introduces our human resource development initiatives, which are the source of the Group's growth. With the aim of systematically developing human resources and acquiring expertise, OLBA Academy (Orba Academy) internal training system provides seamless opportunities for learning according to the stages of individual employees. We are also working to expand our e-Learning courses.

Our goal is to gain a deep understanding of the medical and nursing care areas and acquire product knowledge in order to propose products and services that contribute to solving customer issues.

We believe that investment in human resource education will improve employee engagement and contribute to building employee expertise, skills and management skills, and will be a source of competitive advantage. We will continue such efforts in the future.

New Structure after Business Integration with Part Pass of Both Companies

New structure after the integration of the two companies' parts paths



OLBA HEALTHCARE HOLDINGS

" Aiming to develop medical science,
medical care, and long-term nursing
care through our business endeavors "



DVx

"Protecting Life and QOL."

New structure after the management integration (established
September 1, 2026)

New company name: "OLBA DVx HEALTHCARE,Inc."

New Group Name: OLBA DVx Group

Head Office: Okayama and Tokyo



37

©OLBA HEALTHCARE HOLDINGS, Inc.

This section explains the management integration and changes in the company's name. Companies and DVX Co., Ltd (DVx) will integrate their management on September 1, 2026.

The management of DVx will be merged with "Contribute to the development of medicine, medical care, and nursing care through business, and contribute to the healthy and longevity of the national" as part of our business, and "Protect life and health" as part of our business.

The two companies that aspire to the future of healthcare and people's health will become one, and will reborn as Orbadev-X Healthcare Co., Ltd. The new group name will be "Orbadev-X Group," with two headquarters in Okayama and Tokyo.

Evolve into a "hybrid-type dealership" through the merger of the two companies

Evolve into a "hybrid dealer" through the merger of the two companies

 OLBA HEALTHCARE HOLDINGS Comprehensive foundation on the Chushikoku area Comprehensive medical device sales business that boasts a product group • Founded: 1921 (established in 1967) • Listing: Standard market (Securities code: 2689) • Strengths: Overwhelming market share in Chugoku and Shikoku, Comprehensiveness of SPD and nursing care areas • Issues: Expansion into urban areas (Kanto, etc.), Further strengthen purchasing bargaining power	 DVx Specialized medical device sales business focused on the cardiovascular and arrhythmia fields, mainly in the Kanto area • Established: 1986 • Listing: Standard market (Securities code: 3079) • Strengths: Highly specialized products Sales capabilities of (heart pacemakers, etc.) • Issues: Expand of fields other than cardiovascular, outside the Kanto region Approach to
 Becoming a Hybrid Dealer through the Combination of the Two Companies Aiming to Become an Essential Partner in Hospital Management through the Integration of "Comprehensive × Specialist" • Complementing commercial areas and products: Strong network by mutually complementing Kanto and Chugoku Shikoku • Improve purchasing and optimize logistics: Improve bargaining power and improve inventory efficiency through scale merits 38 ©OLBA HEALTHCARE HOLDINGS, Inc.	

I would like to explain the evolution of the merger between the two companies into a hybrid-type dealer. Company Orba Healthcare Holdings is a comprehensive medical device sales business with an overwhelming market share and a comprehensive product lineup based on Chugoku-Shikoku.

On the other hand, DVx is a specialized medical device sales business with strengths in the cardiovascular and arrhythmia fields, such as heart pacemakers, mainly in the Kanto region.

By integrating these two companies, we will evolve into a hybrid dealer that combines comprehensive and specialized services. In addition to mutually complementing the commercial areas and products in the Kanto region and Chugoku-Shikoku, we will aim to become an essential partner in hospital management by improving purchasing and optimizing logistics by leveraging the merits of scale.

Five Synergies from the Business Integration

Five Synergies from the Management Integration

Business growth (aggressive synergy)	Strengthen foundation (defensive synergy)	Improve organizational strength (synergy of foundation)
01 Expansion of agency business and economies of scale Establish a nationwide sales network by mutually complementing the commercial areas and products of the Kanto region and Chushikoku region. - Mutual complement of commercial areas: reciprocal deployment of medical equipment to the Kanto region and cardiovascular products to Chugoku-Shikoku - Strengthen purchasing bargaining power: Reduce costs and improve profit margins by expanding procurement scale	03 Optimize logistics and inventory and strengthen BCP The company aims to reduce costs and optimize supply by integrating the distribution network and mutual use of the Shin-Okayama Distribution Center. - Reduction of waste loss: Mutual distribution of medical equipment with expiration dates and improvement of inventory turnover - Strong infrastructure: Low dependence on regions, stable supply system even in times of disaster	05 Strengthen development through knowledge sharing and personnel exchanges Share the advanced expertise of both companies and strengthen the human resources foundation of the entire Group. - Education collaboration: Training by specialized personnel and mutual use of educational content - Skill improvement: Bolstering organizational strength through personnel exchanges with different strengths
02 Expand sales channels for in-house products and strengthen medical-industrial collaboration Expand sales channels for DVx products planned in-house to Chugoku-Shikoku and Thailand. Collaborate also with repair support systems. - Developed products: RAQUOS, Holter analysis, super-hearing devices, etc. - Joint development: Strengthen product development capabilities including venture collaboration by sharing on-site needs	04 Streamlining IT spending and data-utilization (DX) Promote the sharing of systems and product masters and efficient joint investment in large-scale systems. - System utilization: Promote the use of both companies' integrated logistics system "Li-Flu" - Co-investment: Invest in sales and logistics IT base against the backdrop of improved financial strength	DVx's in-house planned RAQUOS 

39

COLBA HEALTHCARE HOLDINGS, Inc.

I will explain the five synergies that resulted from the management integration. Under this merger, we will create synergies based on the three axes of offense, defense, and foundation.

First, I would like to point out two proactive synergies for business growth. In terms of "expansion of distributor business and economies of scale," we will establish a nationwide, robust sales network through the provision of medical equipment in the Kanto region and the mutual development of cardiovascular products in Chugoku-Shikoku. We also aim to reduce costs and improve profit margins by expanding the scale of procurement.

To "expand sales channels for our products and strengthen medical-industrial collaborations," DVx will expand sales channels for its in-house planned products such as "RAQUOS," "Holter Analysis," and "Super Hearing Diagnostics" to Chugoku-Shikoku and Thailand. We will also collaborate in the repair support system. Furthermore, we will strengthen our product development capabilities by sharing on-site needs and collaborating with venture companies.

Next, we will focus on defensive synergies to strengthen our foundations. Under the "Optimization of Logistics and Inventory and Strengthening of BCP," we will integrate our distribution network and mutually utilize the Shin-Okayama Distribution Center to mutually accommodate medical devices with expiration dates and reduce waste losses. At the same time, we will build a stable supply system even in the event of a disaster because of low dependence on the local community.

Under IT Investment Efficiency and Data Utilization (DX), we will promote the use of Li-Flo logistics integrated system by both companies to share product masters and make efficient joint investments in IT infrastructure for sales and logistics.

This is about the synergy of the foundation for improving organizational strength. To "strengthen development through knowledge sharing and personnel exchanges," we will raise the human resource base and organizational strength of the entire Group through training by specialized personnel, mutual use of educational content, and personnel exchanges with different strengths.

Evolution of Our Strengths and Weaknesses Led by Integrated Synergies

Evolve our strengths and weaknesses, driven by integration synergies

Leverage strengths: Chugoku-Shikoku share Kanto Cardiovascular Shares No.1 ⇒ Trust of customers and suppliers [Evolution] • Developing DVx's advanced cardiovascular products to a strong foundation in Chugoku-Shikoku • Reinforce dominance within the region and create a reinvestment spiral from earnings to new investments (new businesses, DX, etc.) • Sharing the educational and knowledge of both companies to further strengthen human resource development and DX investment	Overcoming Weaknesses ①: Low profit margin (wholesale characteristics) ⇒ Develop high-value-added businesses and in-house planned products [Evolution] • Achieve higher profit margins by reducing procurement costs through expansion of procurement scale and increasing the ratio of products developed in-house • In addition to the current development in Thailand, expand domestic and Asian sales channels for products developed in-house in DVx (RAQUOS) with sole sales agency rights (e.g., super-hearing devices)	Overcoming Weaknesses ②: Low share in major metropolitan areas ⇒ Development of Olba products in the Kanto region (non-cardiovascular, automated settlement machine business, etc.) [Evolution] • Securing Shares in Major Metropolitan Areas through Integration with DVx with a Strong Foundation in Kanto • Expanding All Olba Products into the Huge Kanto Market • Approximately 40% of automatic checkout machines operate in the Kanto region, Accelerate development of other new businesses, etc.
New growth brought about by our corporate culture of continuing to take on the challenge of change In the company of our 100-year history, we have always taken on challenges without fear of change. We have positioned employee training as a source of growth. We are also focusing on creating new businesses and promoting DX. Through this business merger with DVx on an equal footing, we will combine the strengths and cultures of both parties to create a new growth-oriented path.		



We will explain the evolution of our strengths and weaknesses, which are driven by integration synergies. First, we will leverage our strengths. Leveraging our market share in Chugoku-Shikoku and our trust in Kanto-based cardiovascular market share No.1, we will develop DVx's advanced cardiovascular products in the Chugoku-Shikoku market.

We will create a reinvestment spiral from earnings to new investments and further strengthen human resource development and DX investment.

Next, as a first step to overcome weaknesses, we will achieve an increase in profitability by reducing procurement costs and raising the ratio of products developed in-house to lower profit margins due to the characteristics of wholesale. We will expand domestic and Asian sales channels for products developed in-house by DVx and equipment with exclusive distribution rights, such as RAQUOS and ultra-hearing examiners.

Second, we will secure a share of the market by combining our low share in metropolitan areas with DVx, which has a strong foundation in the Kanto region. We will accelerate the development of markets for all Olva products, as well as automated payment machines and new businesses, where approximately 40% of the products are in operation in the Kanto region.

Even after our 100-year history, we have always taken on challenges without fear of change. We have positioned employee training as a source of growth. We are actively working to create new businesses and promote DX.

Through this management merger with DVx, we will link the strengths and cultures of both parties to create a new growth-oriented trajectory.

End

At the end



OLBA HEALTHCARE HOLDINGS



DVx



We will make every effort to further increase our corporate value and contribute to social as a new "OLBA DVx Group" in unison.

We will make every effort to further increase our corporate value and contribute to social as a new "Olvadive IX Group" in a unified effort.


This is the end of the explanation of the fiscal 2026 report. Thank you very much for watching.

Corporate Data (As of the end of June 2026)

Trade name Olbas Healthcare Holding Inc
(Former name: Kawanishi Holdings Co., Ltd.)
Head Office 1-3, Shimo-Ishii 1-chome, Kita-ku, Okayama
Founded in May 1921
Established October 1967.
Representative Director and President Yohei Maeshima
Capital 607750000 yen
Employees 1405 (Consolidated, as of the end of June 2026)
Fiscal Year Ended June

Mar. 2020 Listed on the First Section of the TSE
Stock Exchange
2022 Apr. Transitioned to standard market

OLBA HD



Diverse business portfolio encompassing orthopedics, cardiovascular, surgical, ophthalmology, and nursing care

43

©OLBA HEALTHCARE HOLDINGS, Inc.

History

May, 1921	Established Kawanishi Kikai Store in Ounji-cho, Okayama City (currently Chuo-cho, Kita-ku, Okayama City).
Sep. 1927	Associated company Kawanishi Machinery Shop reorganized and established.
Jun 1950	Reorganized and established Kawanishi Kikiten Co., Ltd.
1967 Oct	Reorganized and established Kawanishi Medical Equipment Co., Ltd.
1985 Oct	Established Life Care Co., Ltd.
Jul 1996	Established Hosnet Japan Co., Ltd.
1999 Jan.	Merged with three companies, Kagawa Seiki Co., Ltd. and Shikoku Medical Abilities Co., Ltd. At the same time, the company changed its name to Kawanishi Co., Ltd.
2000 Dec	Listed on the Second Section of the Tokyo Stock Exchange.
2004 Jan.	The business division was established as Kawanishi Co., Ltd. through a new split company. At the same time, the company changed its name to Kawanishi Holdings Co., Ltd.
Jun 2005	Acquired 100% of the shares of Nikko Medical Instruments Co., Ltd.
2012 Jan.	Acquired 100% of the stock of Sansey Medical Machinery Co., Ltd.
2014 Aug.	Head office moved to 1-1-3, Shimo-Ishii, Kita-ku, Okayama, in line with the expansion of the Group's business scope.
2016 Jan.	Established Exora Medical Co., Ltd.
Jul 2019	Established Kawanishibarkmed Co., Ltd.
2020 Mar	Listed on the Second Section of the Tokyo Stock Exchange to the First Section of the Tokyo Stock Exchange.
2021 Jan.	To commemorate its 100th anniversary, the company changed its name to Olba Healthcare Holdings, Inc.
2022 Apr	Transitioned to a standard market in accordance with a review of market categories on the Tokyo Stock Exchange.
Jun 2022	Acquired 100% of the shares of Kawanishibarkmed Co., Ltd.
2023 Jan.	Established Thailand Healthcare Co., Ltd. (THAI OLBA Healthcare Co., Ltd.) in the Kingdom of Thailand.
2025 Jan.	Orsid Co., Ltd. was established.

44

©OLBA HEALTHCARE HOLDINGS, Inc.

OLBA Employee Charter

Business Structure

- Contribute to the development of medicine, medical care, and nursing care through business and contribute to the health and longevity of the national
- Promptly and appropriately provide patients and medical providers with the benefits of innovative new features and technologies
- In good faith and continuously to our stakeholders (customers, business partners, employees, local communities, and shareholders)
Providing Value and Pursuing Sustainable Management
- Actively interact inside and outside the industry, foster creativity, and explore frontiers from a global perspective

Organizational Structure

- Respect for human resource development and place emphasis on "management (through human resources)"
- Emphasizing Diversity and Recognizing Diverse Opinions, Values, and Working Styles
- Try to compete and trade fairly at any time
- Results from competition are reinvested to create new value
- Develop an environment where members can be healthy both mentally and physically and have a willingness to contribute

How Members Are

- Have a willingness to grow voluntarily and independently
- Continue to learn modestly without being comfortable with past results
- Not good at free riding to benefit without their own contributions or efforts
- Respect business partners inside and outside the company and engage in business with high ethical standards and pride

45

OLBA HEALTHCARE HOLDINGS, Inc.

Consolidated Balance Sheets (Fiscal Year Ended June 2026)

Millions of yen

Assets	Amount	Change	Liabilities and Net Assets	Amount	Change
Cash and deposits	2,640	Δ829	Trade payables	26,836	Δ206
Trade receivables	26,901	531	Short-term borrowings	850	450
Commodities	6,844	427	Other	2,384	4
Other	688	21	Total current liabilities	30,070	248
Total current assets	37,073	150	Long-term debt	1,116	Δ400
Tangible fixed assets	5,921	417	Other	2,406	129
Intangible fixed assets	625	0	Total long-term liabilities	3,522	Δ271
Investments and other assets	3,033	215	Total liabilities	33,592	Δ23
Total fixed assets	9,579	632	Total net assets	13,061	805
Total assets	46,653	782	Total liabilities and net assets	46,653	782

※ Change from previous year-end

Net assets per share 2,203.27 yen

46

OLBA HEALTHCARE HOLDINGS, Inc.

Consolidated Statements of Cash Flows (Fiscal 2026)

	Millions of yen	FYE June 2025	FYE June 2026
Income before income taxes		1,919	1,775
Depreciation and amortization		628	743
Impairment loss		26	-
Decrease (increase) in notes and accounts receivable-trade (increase in Δ)		$\Delta 256$	$\Delta 531$
Decrease (increase) in inventories (increase in Δ)		$\Delta 399$	$\Delta 427$
Increase (decrease) in notes and accounts payable-trade (decrease in Δ)		843	$\Delta 206$
Other		$\Delta 1,135$	$\Delta 490$
Operating cash flow		1,626	864
Payment for acquisition of tangible fixed assets		$\Delta 1,445$	$\Delta 1,253$
Proceeds from sales of tangible fixed assets		2	396
Purchases of intangible assets		$\Delta 39$	$\Delta 221$
Other		$\Delta 153$	$\Delta 27$
Investing cash flow		$\Delta 1,635$	$\Delta 1,105$

47

COLBA HEALTHCARE HOLDINGS, Inc.

Consolidated Statements of Cash Flows (Fiscal 2026)

	Millions of yen	FYE June 2025	FYE June 2026
Net increase (decrease) in short-term borrowings (Δ)		$\Delta 600$	450
Proceeds from long-term debt		2,000	-
Repayments of long-term debt		$\Delta 83$	$\Delta 400$
Repayments of lease obligations		$\Delta 156$	$\Delta 148$
Purchase of treasury stock		$\Delta 135$	-
Proceeds from sales of treasury stock		139	1
Dividends paid		$\Delta 488$	$\Delta 493$
Other		9	-
Financial cash flow		686	$\Delta 590$
Net increase (decrease) in cash and cash equivalents (decrease in Δ)		678	$\Delta 829$
Cash and Cash Equivalents at Beginning of Year		2,681	3,420
Other		61	-
Cash & cash equivalents at year-end		3,420	2,590

48

COLBA HEALTHCARE HOLDINGS, Inc.

Consolidated Financial Data ①

Item	Unit	2022/6	2023/6	2024/6	2025/6	2026/6
Net sales	Millions of yen	107,959	110,472	118,564	122,702	126,595
Operating income	Millions of yen	2,073	2,151	2,226	1,979	1,679
Recurring Profit	Millions of yen	2,119	2,158	2,244	1,962	1,664
Net income attributable to shareholders of parent company	Millions of yen	1,535	1,414	1,500	1,430	1,112
Net income	Millions of yen	9,093	10,327	11,373	12,255	13,061
Net assets	Millions of yen	39,968	40,878	43,237	45,871	45,653
Total assets	Millions of yen	1,513.91	1,712.19	1,922.58	2,068.59	2,203.27
BPS	Yen	252.80	234.90	251.68	241.43	187.67
EPS	Yen	22.8	25.3	26.3	26.7	28.0
Equity ratio	%	17.8	14.6	13.8	12.1	8.8
ROE	%	5.5	5.3	5.3	4.4	3.6
ROA	%	6.63	7.70	8.01	8.30	10.13
PER	Times	1.11	1.06	1.05	0.97	0.86
PBR	Times					

49

©COLBA HEALTHCARE HOLDINGS, Inc.

Consolidated Financial Data ②

Item	Unit	2022/6	2023/6	2024/6	2025/6	2026/6
Sales CF	Millions of yen	2,420	Δ659	2,084	1,626	864
Investment CF	Millions of yen	Δ211	Δ306	Δ673	Δ1,635	Δ1,105
Finance CF	Millions of yen	Δ1,169	175	Δ1,089	686	Δ590
Cash and cash equivalents	Millions of yen	3,149	2,359	2,681	3,420	2,590
Bank loans	Millions of yen	275	955	600	1,916	1,966
Number of employees	People	1,289	1,317	1,354	1,393	1,405
Medical equipment	People	938	955	982	1,011	1,026
Of which, SPD	People	175	177	174	179	184
Nursing care	People	135	138	147	153	150
Of which, headquarters	People	41	47	51	50	45

50

©COLBA HEALTHCARE HOLDINGS, Inc.

Summary of Fiscal 2026 Results

※New highs for net sales Net sales 126.5 billion yen (+3.2% YoY)	ROE 8.8% (5-year average of 13.4%)	Dividend yield 4.2% (*As of June 30, 2026)
Operating income 1.67 billion yen (15.2% year-on-year Δ)	PBR 0.86 times (*As of June 30, 2026)	DOE Dividends on Equity 3.9% (*As of June 30, 2026)

51

©OLBA HEALTHCARE HOLDINGS, Inc.

CSR Initiatives Contributing to Social Rooted in Local Communities

Working together with local residents to create a future conducive to regional development and revitalization

Faziano Okayama Club sponsor

Established in 2006 as Okayama Prefecture's first professional soccer club
Decided to be promoted to J1 in 2024



MedTech Angels Support for HealthTech Venture

Medical device startup venture contest



Okayama Rivets Team sponsor

Male Table Tennis Team established in 2018
Participated in the national T League



Ohara museum of art Official partner



Established in 1930 in Kurashiki City, Okayama Prefecture
Japan's first private art museum focusing on western art

52

©OLBA HEALTHCARE HOLDINGS, Inc.

"Study Group on the Latest Trends in Overseas Medical Devices" by the Japan Medical Manufacturing Commons MINC

On Medical Globe

Sharing and discussing information on the latest overseas medical device information among various industries

Doctors, manufacturers, the Ministry of Economy, Trade and Industry, the Ministry of Health, Labour and Welfare, the Patent Office, AMED • PMDA



53

OLBA HEALTHCARE HOLDINGS, Inc.

Corporate Information/Inquiries

[Fiscal year] From July 1 to June 30 of the following year

[Ordinary General Meeting of Shareholders] Held annually in September

[Stock Exchange Lists] Tokyo Stock Exchange (Standard Market)

Securities code: 2689


[Number of shares per unit] 100 shares

[Contact] OLBA HEALTHCARE HOLDINGS, INC.

Nobuyuji Murata Managing Director, Chief Administrative Officer
info@olba.co.jp

54

OLBA HEALTHCARE HOLDINGS, Inc.

- 
-
- Although the datum provided in this document is intended to be used with all possible care, the accuracy and completeness of such information is not guaranteed.
 - Opinions and forecasts contained in the data are our forecasts based on information available at the time of preparation of the materials, and we do not guarantee any compensation for the results of using such opinions and forecasts. The information in this document is subject to change without notice.
 - This material is intended to provide a better understanding of us and is not necessarily intended as a recommendation to invest. We asked investors to make their own decisions on the final outcome of their investments.